Common use of Right of Participation and First Refusal Clause in Contracts

Right of Participation and First Refusal. (i) Other than arrangements that are in place or disclosed in SEC Documents prior to the date of this Agreement (including, without limitation, the equity financing agreement entered into between the Company and GHS Investments, LLC, on or around September 1, 2021 (the “Equity Line”)), from the date of this Agreement until the Note is extinguished in its entirety, the Company will not, (i) directly or indirectly, offer, sell, grant any option to purchase, or otherwise dispose of (or announce any offer, sale, grant or any option to purchase or other disposition of) any of its or its Subsidiaries’ debt, equity, or equity equivalent securities, including without limitation any debt, preferred shares or other instrument or security that is, at any time during its life and/or under any circumstances, convertible into, exchangeable, or exercisable for Common Stock (any such offer, sale, grant, disposition or announcement, being referred to as a “Subsequent Placement”) or (ii) enter into any definitive agreement with regard to the foregoing, in each case unless the Company shall have first complied with this Section 4(d).

Appears in 11 contracts

Samples: Securities Purchase Agreement (Clean Energy Technologies, Inc.), Securities Purchase Agreement (Clean Energy Technologies, Inc.), Securities Purchase Agreement (Clean Energy Technologies, Inc.)

AutoNDA by SimpleDocs

Right of Participation and First Refusal. (i) Other than the contemplated financing transactions with the parties set forth in Schedule 4(d) and arrangements that are in place or disclosed in SEC Documents Documents, and any future amendments thereto, prior to the date of this Agreement (including, without limitation, the equity financing agreement entered into between the Company and GHS Investments, LLC, on or around September 1, 2021 (the “Equity Line”))Agreement, from the date of this Agreement until the later of (i) twelve (12) calendar months after the date of this Agreement or (ii) the date that the Note is extinguished in its entirety, the Company will not, (i) directly or indirectly, offer, sell, grant any option to purchase, or otherwise dispose of (or announce any offer, sale, grant or any option to purchase or other disposition of) any of its or its Subsidiaries’ debt, equity, or equity equivalent securities, including without limitation any debt, preferred shares or other instrument or security that is, at any time during its life and/or under any circumstances, convertible into, exchangeable, or exercisable for Common Stock (any such offer, sale, grant, disposition or announcement, announcement being referred to as a “Subsequent Placement”) or (ii) enter into any definitive agreement with regard to the foregoing, in each case unless the Company shall have first complied with this Section 4(d).

Appears in 3 contracts

Samples: Registration Rights Agreement (NKGen Biotech, Inc.), Registration Rights Agreement (NKGen Biotech, Inc.), Registration Rights Agreement (NKGen Biotech, Inc.)

Right of Participation and First Refusal. (i) Other than the contemplated financing transactions with the parties set forth in Schedule 4(d), and arrangements that are in place or disclosed in SEC Documents Documents, and any future amendments thereto, prior to the date of this Agreement (including, without limitation, the equity financing agreement entered into between the Company and GHS Investments, LLC, on or around September 1, 2021 (the “Equity Line”))Agreement, from the date of this Agreement until the later of (i) twelve (12) calendar months after the date of this Agreement or (ii) the date that the Note is extinguished in its entirety, the Company will not, (i) directly or indirectly, offer, sell, grant any option to purchase, or otherwise dispose of (or announce any offer, sale, grant or any option to purchase or other disposition of) any of its or its Subsidiaries’ debt, equity, or equity equivalent securities, including without limitation any debt, preferred shares or other instrument or security that is, at any time during its life and/or under any circumstances, convertible into, exchangeable, or exercisable for Common Stock (any such offer, sale, grant, disposition or announcement, announcement being referred to as a “Subsequent Placement”) or (ii) enter into any definitive agreement with regard to the foregoing, in each case unless the Company shall have first complied with this Section 4(d).

Appears in 1 contract

Samples: Registration Rights Agreement (NKGen Biotech, Inc.)

AutoNDA by SimpleDocs

Right of Participation and First Refusal. (i) Other Provided the Buyers have fully complied with the terms of this Agreement, including timely payment of the Purchase Price, other than arrangements that are in place or disclosed in SEC Documents prior to the date of this Agreement (including, without limitation, the equity financing agreement entered into between the Company and GHS Investments, LLC, on or around September 1, 2021 (the “Equity Line”))Agreement, from the date of this Agreement until twenty four (24) months following the Note is extinguished in its entiretydate of this Agreement, the Company will not, (i) directly or indirectly, offer, sell, grant any option to purchase, or otherwise dispose of (or announce any offer, sale, grant or any option to purchase or other disposition of) any of its or its Subsidiaries’ debt, equity, or equity equivalent securities, including without limitation any debt, preferred shares or other instrument or security that is, at any time during its life and/or under any circumstances, convertible into, exchangeable, or exercisable for Common Stock any class of Ordinary Shares (any such offer, sale, grant, disposition or announcement, announcement being referred to as a “Subsequent Placement”) or (ii) enter into any definitive agreement with regard to the foregoing, in each case unless the Company shall have first complied with this Section 4(d), other than contemplated purchase and sale by the Company of an additional US$1,500,000 of Ordinary Shares and Warrants.

Appears in 1 contract

Samples: Securities Purchase Agreement (AnPac Bio-Medical Science Co., Ltd.)

Time is Money Join Law Insider Premium to draft better contracts faster.